24/7 Wall Street
16 Sept 2026, 15:36 UTC · 1h ago
Verdict
Headline leans bullish. We score JNJ +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Johnson & Johnson raised full-year 2026 guidance to reported sales of $101.1 billion at the midpoint and adjusted operational EPS of $11.50 to $11.65.
Priced inanalysis of Q2 2026 call
So whatThis guidance supports the current 54.35% one-year price surge and sets the bar for the next earnings print.
More positive than 91% of claims this week
Realty Income's net debt/EBITDA stands at 7.9x with 65.7% of annualized base rent coming from non-investment-grade tenants.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of existing metrics
So whatWith 10-year Treasuries at 4.97%, this leverage profile compresses the spread between risk-free yield and O's 5.26% payout.
More negative than 80% of claims this week
Johnson & Johnson reports growth for key products DARZALEX at 22.5% and TREMFYA at 68.3%.
Priced inanalysis of Q2 2026 results
So whatThese high-growth segments provide the organic fuel to sustain the 64-year dividend increase streak into 2027.
More positive than 65% of claims this week
Realty Income guided full-year 2026 AFFO per share to a range of $4.44 to $4.45.
Priced inanalysis of existing guidance
So whatThe midpoint represents ~4% growth, suggesting a slow-growth trajectory compared to JNJ's high-growth drug engines.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Praised for its 64-year dividend streak, AAA-caliber balance sheet, and superior long-term total returns.
More negative than 73% of ticker scores this week
Criticized for high leverage, exposure to non-investment-grade tenants, and interest-rate vulnerability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
23m ago
+0.1%
Price flat so far
$267.46 vs $267.20 close before publication (Sep 15) · not market-adjusted
JNJ chart →
